Aditxt (ADTX) & Its Peers Critical Contrast

Aditxt (NASDAQ:ADTX) is one of 248 public companies in the “MED – DRUGS” industry, but how does it compare to its peers? We will compare Aditxt to related companies based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Aditxt and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1	0	0	0	1.00
Aditxt Competitors	1942	3674	9717	393	2.54

As a group, “MED – DRUGS” companies have a potential upside of 77.05%. Given Aditxt’s peers stronger consensus rating and higher probable upside, analysts plainly believe Aditxt has less favorable growth aspects than its peers.

Institutional and Insider Ownership

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 13.6% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Aditxt has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Aditxt’s peers have a beta of 1.28, suggesting that their average stock price is 28% more volatile than the S&P 500.

Profitability

This table compares Aditxt and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aditxt	-206,431.38%	-316.98%	-80.88%
Aditxt Competitors	-19,401.86%	-92.54%	-16.38%

Valuation and Earnings

This table compares Aditxt and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aditxt	$130,000.00	-$34.45 million	0.00
Aditxt Competitors	$30.16 billion	$57.36 million	-3.36

Aditxt’s peers have higher revenue and earnings than Aditxt. Aditxt is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Aditxt peers beat Aditxt on 11 of the 13 factors compared.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.